Bidding war for IMU, page-83

Imugene (ASX: IMU)

No doubt the news regarding Merck and Viralytics caught the eye of the team at Imugene.
The immuno-oncology focused biotech company has been releasing a series of positive news to the market in recent weeks with regards to its cancer fighting technologies currently in development.
This week Imugene revealed that its clinical stage arginine modulator drug candidate had demonstrated anti-tumour activity in 12 different cancer mouse models of the most prevalent cancers, with significant activity in a melanoma cancer model.
The results represent a significant milestone for Imugene and pave the way for the company to move onto more comprehensive trials.
Rather than spend billions on risky research and development, big pharma companies in recent times are opting to acquire smaller biotech companies that show promise and have cleared early stage trials.
With various trials underway, Imugene could come on the radar of big pharma in the future. Although just as easy could a failed clinical trial lead to failure.

https://*********.com.au/reporting-season-asx-expose-zombie-companies/